Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ironwood Pharmaceuti
(NQ:
IRWD
)
4.895
+0.205 (+4.37%)
Streaming Delayed Price
Updated: 11:06 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ironwood Pharmaceuti
< Previous
1
2
3
4
5
6
Next >
Why Shares of VectivBio Holding Are Up Today
May 22, 2023
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock.
Via
The Motley Fool
Merger Monday
May 22, 2023
This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock.
Via
Talk Markets
Why VectivBio Shares Are Surging Monday
May 22, 2023
VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to
Via
Benzinga
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
May 22, 2023
Both companies are working on treatments for gastrointestinal diseases.
Via
Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD
May 22, 2023
Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked
Via
Benzinga
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 22, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Recap: Ironwood Pharmaceuticals Q1 Earnings
May 04, 2023
Via
Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
May 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Earnings Outlook For Ironwood Pharmaceuticals
February 15, 2023
Via
Benzinga
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
April 24, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
April 20, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 13, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
February 02, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session
January 09, 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales...
Via
Benzinga
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
November 03, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
October 20, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
September 06, 2022
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional...
Via
Benzinga
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
September 06, 2022
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
Via
Benzinga
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 06, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
September 01, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.